相关实验视频
Updated: May 28, 2025

04:28
Lung Tumor Cell Recruitment Assay
Published on: February 26, 2019
5.3K
日本癌症患者的第二意见推 - 全国一项研究
Mieko Takasawa1,2, Norihiro Teramoto3, Natsumi Yamashita3
1Division of Health Services Research, National Cancer Center, Tokyo, Japan.
Cancer science
|February 12, 2025
概括
在日本,1.6%的癌症患者寻求了第二意见 (SO),这可能会推迟治疗开始长达22天. 了解SO的好处和风险对于患者护理至关重要.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 患者权利 患者权利
背景情况:
- 第二次意见 (SO) 对于癌症患者的知情决策至关重要.
- 在此之前,日本缺乏关于全国SO实践的客观数据.
- 了解SO转诊模式对于优化癌症护理途径至关重要.
研究的目的:
- 调查日本癌症患者中第二意见 (SO) 转诊的患病率和特征.
- 分析与寻求SO相关的治疗启动潜在延迟.
- 通过全国性注册提供SO实践的客观数据.
主要方法:
- 利用了来自全国医院癌症登记册和2018-2020年诊断程序组合 (DPC) 调查的数据.
- 分析了超过260万名癌症患者的病历,以确定SO转介.
- 检查了转诊率,SO的时间和治疗开始的延迟.
主要成果:
- 1.6%的癌症患者收到了SO推信.
- SO转介率因性别,年龄和地理区域而异.
- 在开始治疗之前寻求SO与开始治疗肺癌和乳腺癌延迟18-22天有关.
结论:
- 日本的癌症患者中很少使用第二意见 (SO) 推,但可能导致治疗延误.
- 需要进一步的研究来平衡治疗延迟的预后影响与SO的心理益处.
- 优化SO过程可能会改善癌症患者的护理和决策.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.7K
10:28Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
Published on: January 22, 2018
10.9K
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Survival Analysis
321
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
321
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K